A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings, published in Nature Cancer, may help improve future ways to deliver this cellular immunotherapy for metastatic non-small cell lung cancer.
TIL therapy is a live cell treatment where a patient’s tumor is surgically removed and sent to a lab where it is dissected to remove the immune cells that have found…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply